RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

被引：0
|
作者：
Hatzivassiliou, Georgia
Song, Kyung
Yen, Lvana
Brandhuber, Barbara J.
Anderson, Daniel J.
Alvarado, Ryan
Ludlam, Mary Jc
Stokoe, David
Gloor, Susan L.
Vigers, Guy
Morales, Tony
Aliagas, Ignacio
Liu, Bonnie
Sideris, Steve
Hoeflich, Klaus
Jaiswal, Bijay S.
Seshagiri, Sonnasekar
Koeppen, Hartmut
Belvin, Marcia
Friedman, Lori S.
Malek, Shiva
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-5753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5753
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Molecular Analysis of the Ras-Raf-MAPK Pathway in Langerhans Cell Histiocytosis
    Solomon, David
    Joseph, Nancy
    Grenert, James
    Horvai, Andrew
    LABORATORY INVESTIGATION, 2015, 95 : 27A - 27A
  • [42] Molecular dissection of the RAS/RAF/MAPK pathway in primary and metastatic melanoma.
    Rother, J.
    Bailey, J.
    Alvarado, G.
    Prieto, V. G.
    Lazar, A. J.
    Jones, D.
    Hwu, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 465S - 465S
  • [43] Abrogation of the paradoxical activation of the MAPK pathway following RAF inhibition by ARQ 680, a potent inhibitor of the RAF family of serine/threonine kinases
    Chen, Chang-Rung
    Szwaya, Jeffrey
    Lapierre, Jean-Marc
    Ashweill, Mark A.
    France, Dennis S.
    CANCER RESEARCH, 2011, 71
  • [44] Mutations in ERBB4 may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway
    Cullum, Richard Lee
    Ghosh, Taraswi
    Lucas, Lauren
    Waits, Damien
    Riese, David
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Oncogenic mutations in BRAF and MEK weaken the ATP-stabilized inactive conformation of RAF to promote RAF dimerization and MAPK pathway activation
    Sudhamsu, Jawahar
    Liau, Nicholas
    Wendorff, Timothy
    Izadi, Saeed
    Gerosa, Luca
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [46] THE TORSO RECEPTOR TYROSINE KINASE CAN ACTIVATE RAF IN A RAS-INDEPENDENT PATHWAY
    HOU, XS
    CHOU, TB
    MELNICK, MB
    PERRIMON, N
    CELL, 1995, 81 (01) : 63 - 71
  • [47] Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors
    McCubrey, James A.
    Milella, Michele
    Tafuri, Agostino
    Martelli, Alberto M.
    Lunghi, Paolo
    Bonati, Antonio
    Cervello, Melchiorre
    Lee, John T.
    Steelman, Linda S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (06) : 614 - 630
  • [48] Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth
    Zanucco, Emanuele
    El-Nikhely, Nefertiti
    Goetz, Rudolf
    Weidmann, Katharina
    Pfeiffer, Verena
    Savai, Rajkumar
    Seeger, Werner
    Ullrich, Axel
    Rapp, Ulf R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (39) : 26804 - 26816
  • [49] Synergism between inhibitors of the EGFR-RAS-RAF-MEK pathway and the WNT pathway
    Cai, Jinjin
    Dorr, Andrew
    Rosenstein, Laurie
    Labdon, Jim
    Li, Xiaojuan
    Zhou, Hang
    Zhou, Yanyuan
    He, Wangjun
    He, Qiuping
    Huang, Xiaoyan
    Parikh, Aparna R.
    Giannakis, Marios
    An, Michael
    CANCER RESEARCH, 2023, 83 (08)
  • [50] Amplification of wild-type BRAF in melanoma is associated with activation of RAF-MEK-ERK signaling and MEK-dependence
    Blumenthal, Ezra
    Poulikakos, Poulikos
    Tadi, Madhavi
    Grbovic-Huezo, Olivera
    Taylor, Barry
    Janakiraman, Manickam
    Leversha, Margaret
    Viale, Agnes
    Solit, David
    Rosen, Neal
    Pratilas, Christine
    CANCER RESEARCH, 2009, 69
12345